{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-26-000086","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2026-07-28T01:01:17+00:00","discovered_at":"2026-07-28T10:05:00.380547+00:00","generated_at":"2026-07-28T10:05:12.907994+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Denali Therapeutics sells rare pediatric disease PRV for $195M","bullets":["Gross proceeds of $195M from sale of PRV to a large pharmaceutical company.","PRV received from FDA approval of AVLAYA (tividenofusp alfa) for Hunter syndrome in March 2026.","Sale closed on July 27, 2026, per asset purchase agreement dated June 12, 2026.","Proceeds provide significant cash infusion; no other terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-26-000086","json":"https://secwatch.observer/filing/0001714899-26-000086.json","markdown":"https://secwatch.observer/filing/0001714899-26-000086.md","text":"https://secwatch.observer/filing/0001714899-26-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/0001714899-26-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T10:05:12.907994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}